Nonsurgical Outpatient Therapies for the Management of Female Stress Urinary Incontinence: Long-Term Effectiveness and Durability

Table 2

Summary of pharmacotherapy trials.

Study	N	Age, y	Treatment	Study design	Study duration	Efficacy measures	Efficacy outcomes
Bump et al. 2008 [36]	Cohort A: 1424; Cohort B: 2515	Cohort A: 53.2; Cohort B: 55.5	Duloxetine 40 mg bid	Pooled analysis; Cohort A: 3 randomized, placebo-controlled, double-blind studies and 1 open-label, single arm trial; Cohort B: one randomized, placebo-controlled, double-blind study	30 mos; 18 mos	Cohort A: PGI-I scores; discontinuation rates; Cohort B: PGI-I scores; diaries; discontinuation rates	PGI-I much or very much better: Cohort A: 71.5%; Cohort B: 57.4%; Decrease in SUI episodes at end point: Cohort A: N/A; Cohort B: ≈70%; Discontinued by 12 months: Cohort A: 57.5%; Cohort B: 79.5%
Vella et al. 2008 [35]	228	N/A	Duloxetine 40 mg bid	Open label, single arm	12 mos	Discontinuation rates	Discontinued by 4 wks: 69%; Discontinued by 12 mos: 91%; At 12 mos, 10 women were on no treatment and had not undergone surgery; of these, 6 were considered cured

Abbreviations: N/A, not available; PGI-I, Patient Global Impression-Improvement rating scale.